IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Regatta Capital Group LLC

Regatta Capital Group LLC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,166 shares of the medical research company’s stock after acquiring an additional 98 shares during the period. Regatta Capital Group LLC’s holdings in IQVIA were worth $426,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Simplify Asset Management Inc. lifted its holdings in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the period. Nordea Investment Management AB raised its position in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Versor Investments LP purchased a new stake in shares of IQVIA during the 3rd quarter worth $1,328,000. JPMorgan Chase & Co. boosted its holdings in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. Finally, CIBC Asset Management Inc boosted its position in IQVIA by 3.3% during the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after purchasing an additional 8,490 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Down 0.7 %

NYSE:IQV opened at $204.54 on Friday. The stock has a fifty day simple moving average of $199.71 and a 200 day simple moving average of $221.06. The firm has a market capitalization of $37.12 billion, a price-to-earnings ratio of 26.84, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

Analyst Ratings Changes

A number of research firms recently commented on IQV. TD Cowen decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Redburn Atlantic initiated coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Barclays dropped their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Wednesday, December 11th. Finally, Evercore ISI decreased their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.